A Seattle biotech offloads lead eye drug in deal valued at $1B+ as it refocuses on emerging pipeline
An FDA-approved drug used to maintain pupil size in patients during cataract surgery and reduce postoperative eye pain has been sold to Rayner Surgical in …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
